Home » Rexahn Pharmaceuticals Granted European Patent for Anti-Cancer Compound
Rexahn Pharmaceuticals Granted European Patent for Anti-Cancer Compound
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical
company commercializing potential best in class oncology and CNS therapeutics, Tuesday announced that the European Patent Office has granted a patent for
its novel anti-cancer compound, RX-3117.
Fox Business
Fox Business
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May